Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03967522
Title Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases (CABRAMET)
Acronym CABRAMET
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Centre Leon Berard
Indications
Therapies
Age Groups: senior | adult
Covered Countries FRA


No variant requirements are available.